Keros Therapeutics Inc
KROS17.570USD
+0.330+1.91%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
713.91MMarket Cap
11.03P/E TTM
More Details of Keros Therapeutics Inc Company
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Keros Therapeutics Inc Info
Ticker SymbolKROS
Company nameKeros Therapeutics Inc
IPO dateApr 08, 2020
CEOSeehra (Jasbir)
Number of employees169
Security typeOrdinary Share
Fiscal year-endApr 08
Address1050 Waltham Street, Suite 302
CityLEXINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02421
Phone16173146297
Websitehttps://www.kerostx.com/
Ticker SymbolKROS
IPO dateApr 08, 2020
CEOSeehra (Jasbir)
Company Executives of Keros Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jasbir Seehra, Ph.D.
Dr. Jasbir Seehra, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
392.72K
+90500.00%
Mr. Julius Knowles
Mr. Julius Knowles
Independent Director
Independent Director
6.44K
+5250.00%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Chairman of the Board
Independent Chairman of the Board
5.45K
+5250.00%
Mr. Nima Farzan
Mr. Nima Farzan
Independent Director
Independent Director
5.25K
+5250.00%
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Director
Independent Director
5.25K
+5250.00%
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
5.25K
+5250.00%
Mr. Keith C. Regnante
Mr. Keith C. Regnante
Chief Financial Officer
Chief Financial Officer
--
-44000.00%
Mr. Justin Frantz
Mr. Justin Frantz
Head of Investor Relations
Head of Investor Relations
--
--
Dr. Alpna Hansraj Seth, Ph.D.
Dr. Alpna Hansraj Seth, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lorena Lerner, Ph.D.
Dr. Lorena Lerner, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jasbir Seehra, Ph.D.
Dr. Jasbir Seehra, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
392.72K
+90500.00%
Mr. Julius Knowles
Mr. Julius Knowles
Independent Director
Independent Director
6.44K
+5250.00%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Chairman of the Board
Independent Chairman of the Board
5.45K
+5250.00%
Mr. Nima Farzan
Mr. Nima Farzan
Independent Director
Independent Director
5.25K
+5250.00%
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Director
Independent Director
5.25K
+5250.00%
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
5.25K
+5250.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Feb 4
Updated: Wed, Feb 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Madison Avenue Partners LP
8.89%
Tang Capital Management, LLC
7.94%
BlackRock Institutional Trust Company, N.A.
7.73%
ExodusPoint Capital Management, LP
6.26%
D. E. Shaw & Co., L.P.
5.07%
Other
64.10%
Shareholders
Shareholders
Proportion
Madison Avenue Partners LP
8.89%
Tang Capital Management, LLC
7.94%
BlackRock Institutional Trust Company, N.A.
7.73%
ExodusPoint Capital Management, LP
6.26%
D. E. Shaw & Co., L.P.
5.07%
Other
64.10%
Shareholder Types
Shareholders
Proportion
Hedge Fund
37.82%
Investment Advisor
24.49%
Investment Advisor/Hedge Fund
24.21%
Research Firm
4.64%
Venture Capital
2.82%
Private Equity
2.64%
Corporation
1.89%
Individual Investor
1.79%
Pension Fund
1.13%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
405
29.79M
97.77%
-30.22M
2025Q3
385
41.03M
124.11%
-17.81M
2025Q2
392
46.16M
114.02%
-7.54M
2025Q1
394
39.41M
98.81%
-8.43M
2024Q4
366
43.10M
106.25%
-873.01K
2024Q3
351
43.05M
114.83%
+404.61K
2024Q2
337
39.69M
109.09%
-4.15M
2024Q1
332
39.81M
110.03%
+1.08M
2023Q4
310
34.40M
109.87%
-229.62K
2023Q3
303
31.04M
104.70%
-2.97M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Madison Avenue Partners LP
2.71M
8.89%
+16.75K
+0.62%
Sep 30, 2025
Tang Capital Management, LLC
2.42M
7.94%
+1.00M
+70.47%
Oct 15, 2025
BlackRock Institutional Trust Company, N.A.
2.36M
7.73%
-35.16K
-1.47%
Sep 30, 2025
ExodusPoint Capital Management, LP
1.91M
6.26%
+1.88M
+8204.24%
Nov 10, 2025
D. E. Shaw & Co., L.P.
1.55M
5.07%
+214.52K
+16.11%
Oct 20, 2025
The Vanguard Group, Inc.
2.71M
8.89%
+87.13K
+3.33%
Sep 30, 2025
State Street Investment Management (US)
1.30M
4.28%
-81.28K
-5.87%
Sep 30, 2025
Nantahala Capital Management, LLC
1.23M
4.05%
-387.50K
-23.91%
Sep 30, 2025
Goldman Sachs Asset Management, L.P.
874.78K
2.87%
+412.55K
+89.25%
Sep 30, 2025
Logos Global Management LP
850.00K
2.79%
-1.15M
-57.50%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.76%
ALPS Medical Breakthroughs ETF
0.26%
State Street SPDR S&P Biotech ETF
0.21%
Federated Hermes MDT Small Cap Core ETF
0.12%
Direxion Daily S&P Biotech Bull 3X Shares
0.1%
ProShares Ultra Nasdaq Biotechnology
0.09%
WisdomTree US SmallCap Quality Growth Fund
0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
iShares Biotechnology ETF
0.05%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.76%
ALPS Medical Breakthroughs ETF
Proportion0.26%
State Street SPDR S&P Biotech ETF
Proportion0.21%
Federated Hermes MDT Small Cap Core ETF
Proportion0.12%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.1%
ProShares Ultra Nasdaq Biotechnology
Proportion0.09%
WisdomTree US SmallCap Quality Growth Fund
Proportion0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.06%
Invesco Nasdaq Biotechnology ETF
Proportion0.06%
iShares Biotechnology ETF
Proportion0.05%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
